Previous close | 17.69 |
Open | 17.80 |
Bid | 17.85 x 400 |
Ask | 17.97 x 200 |
Day's range | 17.20 - 17.97 |
52-week range | 16.92 - 41.06 |
Volume | |
Avg. volume | 1,690,837 |
Market cap | 2.186B |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.28 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 39.88 |
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths. It's already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
PALO ALTO, Calif., March 13, 2024--ECLIPSE study to be published in NEJM shows Shield blood-based screening test detects 83% of people with colorectal cancer.
PALO ALTO, Calif., March 06, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 29,048 shares of its common stock to one new non-executive employee with a grant da